A Phase Ib/II,Multi-center, Open, Multiple-dose Design to Evaluate the Safety,Tolerability and Efficacy of STSP-0601 for Injection in Patients With Inhibitory Hemophilia
Latest Information Update: 17 Nov 2023
At a glance
- Drugs STSP-0601 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Staidson Beijing BioPharmaceuticals
- 09 Aug 2023 Status changed from recruiting to completed.
- 14 Feb 2023 Results(n=7) assessing the efficacy and safety of STSP-0601 in preclinical and clinical studies published in the Journal of Thrombosis and Haemostasis
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition